All data are based on the daily closing price as of December 24, 2024
k
Kaken Pharmaceutical
4521.TSE
26.89 USD
-0.30
-1.10%
Overview
Last close
26.89 usd
Market cap
1.02B usd
52 week high
29.49 usd
52 week low
20.71 usd
Target price
22.93 usd
Valuation
P/E
9.0807
Forward P/E
N/A
Price/Sales
1.8354
Price/Book Value
1.0442
Enterprise Value
516.52M usd
EV/Revenue
0.9295
EV/EBITDA
3.1138
Key financials
Revenue TTM
555.70M usd
Gross Profit TTM
264.82M usd
EBITDA TTM
167.06M usd
Earnings per Share
3.07 usd
Dividend
0.48 usd
Total assets
1.09B usd
Net debt
-298.61M usd
About
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001 that is in phase II clinical trial for the treatment of refractory vascular malformations; BBI-4000 that is in phase I clinical trial for primary palmoplantar hyperhidrosis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; Seladelpar that is in phase I clinical trial for primary biliary cholangitis; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.